By The Burrill Report:
By Vinay Singh
Johnson & Johnson (JNJ) released interim data from a late-stage study that showed its prostate cancer drug, Zytiga, improved survival of men with less advanced forms of the disease. The newly released data may help expand the indication of the already approved drug to treat a larger patient pool.
The EU Committee for Medicinal Products for Human Use recently recommended Roche Holding Ltd.’s (RHHBY) experimental therapy drug Avastin – which, used in combination with chemotherapy, is a treatment for women with platinum-resistant ovarian cancer – for approval by the European Commission. The drug has already been approved for use as a first-stage treatment option for patients suffering from late-stage ovarian cancer.
By John Eastman:As Prostate cancer cases continue to be diagnosed in the U.S. in abundance (estimated 238,590 new cases of prostate cancer will be diagnosed with nearly 30,000 deaths) drug makers are also intensifying their effort to confront this late stage of life disease in men. The average age at the time of diagnostics is 67.
By Peter Geschek:
In its first full year on the market, in 2012, Johnson & Johnson's prostate cancer medicine Zytiga generated $961 million in revenues which make it a "near blockbuster". (A drug is considered blockbuster above $1 billion in sales).Zytiga is the most successful oral oncology drug launch in history. It is now approved in 65 countries and helped a huge number of men everywhere.
ByEmerging Equities:These are exciting times for Johnson & Johnson (JNJ) with FDA product approvals setting the stage for higher growth. Recently the FDA approved Johnson & Johnson's drugs Zytiga for prostrate cancer, Invokana for type 2 diabetes, and Invega for schizophrenia.
The Burrill Report submits: Shares of Affymax (AFFY) tumbled 65 percent on news that despite a set of late-stage trials of its anemia drug Hematide that showed it was not inferior to Amgen’s (AMGN) Epogen or Aranesp, a subgroup of pre-dialysis patients had a statistically significant increase in cardiovascular events.
By Theodore Cohen:The 2013 Genitourinary ("2013 GU") Cancers Symposium, A Transformative Multidisciplinary Approach, to be held 14-16 February, 2013, includes multiple poster sessions on Dendreon's (DNDN) Provenge (sipuleucel-T) that will be of major interest to the medical community in general and practitioners treating prostate cancer in particular.
The Burrill Report submits: Shares of Cambridge, Massachusetts-based Curis (CRIS) fell nearly 50 percent on news that its experimental drug in combination with Avastin and chemotherapy failed in a mid-stage trial in metastatic colorectal cancer.